- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/4245 - Oxadiazoles
Patent holdings for IPC class A61K 31/4245
Total number of patents in this class: 2404
10-year publication summary
|
158
|
136
|
153
|
188
|
215
|
193
|
162
|
162
|
127
|
33
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 5080 |
47 |
| Takeda Pharmaceutical Company Limited | 2961 |
44 |
| PTC Therapeutics, Inc. | 492 |
44 |
| Merck Sharp & Dohme LLC | 3689 |
44 |
| Novartis AG | 11238 |
43 |
| F. Hoffmann-La Roche AG | 7958 |
34 |
| Astellas Pharma Inc. | 1145 |
34 |
| The Scripps Research Institute | 1364 |
23 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
23 |
| Daiichi Sankyo Company, Limited | 1829 |
22 |
| AstraZeneca AB | 3042 |
21 |
| Chong Kun Dang Pharmaceutical Corp. | 229 |
21 |
| Incyte Holdings Corporation | 609 |
21 |
| Receptos LLC | 65 |
21 |
| Boehringer Ingelheim International GmbH | 4629 |
20 |
| Incyte Corporation | 918 |
20 |
| Hoffmann-La Roche Inc. | 3060 |
18 |
| Glaxo Group Limited | 4496 |
17 |
| Merck Patent GmbH | 5909 |
17 |
| Aurigene Oncology Limited | 64 |
17 |
| Other owners | 1853 |